Dystrophin and the associated glycoprotein complex (DGC)
Dystrophin consists of 3685 amino acids and is a 427 kDa protein (Koenig et al., 1988) . Dystrophin is composed of 4 domains, the first 240 N-terminal aminoacids define the actinbinding domain, which contains two actin-binding sites (Jarrett & Foster, 1995; Koenig & Kunkel, 1990 ). This domain is followed by a central rod shaped domain, consisting of 24 spectrin-like repeat units interrupted by 4 proline-rich hinge regions (Koenig & Kunkel, 1990) . It has been demonstrated that an extra actin binding domain is present between repeats 11 and 17 (Rybakova et al., 1996) and that repeat 16 and 17 contain an nNOS binding site (Lai et al., 2009) . The cysteine-rich domain encompasses aminoacids 3080 to 3360 and includes 15 cysteines, two EF hand motifs and a ZZ domain (Koenig et al., 1988 ) and binds to -dystroglycan. Finally the C-terminal domain consists of the last 325 amino acids involved in protein-protein interactions. Dystrophin is part of the dystrophin-associated glycoprotein complex (DGC) (Figure 1 ). The cysteine-rich and C-terminal domains of dystrophin bind to several parts of the DGC, which can be divided into the dystroglycan complex, the sarcoglycan-sarcospan complex and the cytoplasmatic, dystrophin containing complex (Blake et al., 2002; Yoshida et al., 1994) . In skeletal muscle the dystroglycan complex consists of -dystroglycan and -dystroglycan, which are both heavily glycosylated (Ibraghimov-Beskrovnaya et al., 1992) . Dystrophin binds to -dystroglycan, a transmembrane protein that binds to the extra-cellular -dystroglycan; -dystroglycan on its part binds to the extracellular matrix component laminin-2 (Hohenester et al., 1999; Rentschler et al., 1999; Suzuki et al., 1994) . The sarcoglycan-sarcospan complex includes -, -, -and -sarcoglycan and sarcospan (Blake et al., 2002) . The cytoplasmatic part of the DGC includes dystrophin itself, syntrophin and -dystrobrevin, which binds to both dystrophin and syntrophin (Ahn et al., 1996) . Alpha-syntrophin also binds to dystrophin and, additionally, it recruits the enzyme nNOS to the sarcolemma (Ahn & Kunkel, 1995; Brenman et al., 1995; Yoshida et al., 1995) , although it has been recently demonstrated that the recruitment of nNOS by dystrophin repeats 16 and 17 is more important (Lai et al., 2009) . Dystrophin also binds to and influences microtubules organization in the cytoplasm (Prins et al., 2009) . In BMD patients, internally deleted dystrophins maintaining the Nterminal and C-terminal domains are able to bind to the DGC complex at the sarcolemma Matsumura et al., 1993; Mirabella et al., 1998) , while in DMD patients the absence of dystrophin results in the complete loss or decrease of other DGC proteins, and in the loss of nNOS at the sarcolemma (Brenman et al., 1995; Ervasti et al., 1990; Ohlendieck & Campbell, 1991) . The function of the DGC is still largely unknown. However, since the complex forms a mechanical link between the cytoskeleton and the 
Current treatment
There is currently no therapy for DMD. Nevertheless the lifespan and quality of life of DMD patients has significantly improved during the last 2 decades due to improved health care, especially assisted ventilation (Eagle et al., 2002) . The mean age of death in the 1960s was 14.4 years, whereas for those ventilated since 1990 it was 25.3 years. The chances of survival to 25 years have increased from 0% in the 1960s to 4% in the 1970s and 12% in the 1980s, and that the impact of nocturnal ventilation has further improved this chance to 53% for those ventilated since 1990. Another crucial step has been the use of corticosteroids (mainly prednisone (Moxley, III & Pandya, 2011) and deflazacort (Biggar et al., 2001) ), which reduce the inflammatory response in patients' muscle and the accompanied damage and fibrosis, thus longer maintaining muscle quality. The benefit of corticosteroids has been clearly demonstrated for DMD patients in a double-blind randomized controlled trial in more than 100 boys (Mendell et al., 1989) . Corticosteroids treatment extends the ambulation of patients for about 2 years and reduces scoliosis (King et al., 2007) . The prolonged use of corticosteroids has however known side effects, which include weight gain, hypertension, bone demineralization, vertebral compression fractures and sometimes behavior disorders. Guidelines for DMD patients' management have been published in order to harmonize the standards of clinical practice (Bushby et al., 2010a; Bushby et al., 2010b) .
There are numerous therapeutic approaches under development for DMD. Some aim at addressing specific issues of pathology such as Idebenone, or green tea extract to reduce oxidative stress (Dorchies et al., 2009; Nagy & Nagy, 1990) , or myostatin inhibition to increase muscle mass (Bish et al., 2011; Dumonceaux et al., 2010) , while others directly aim at dystrophin restoration. In this chapter we will focus on the latter.
Therapeutic approaches

Stop codon read-through
This approach has been developed to address nonsense mutations, which are responsible for 14% of DMD cases ). The rationale is to use a compound that interacts with the translation machinery to incorporate an amino acid instead of terminating protein translation at the site of a premature stop codon. This will result in a protein that isaside from a one amino acid change at the location of the stop mutation -completely normal (Aurino & Nigro, 2006; Kaufman, 1999; Linde & Kerem, 2008; Malik et al., 2010a) . This approach can also induce read-through of real stop codons, but this is thought to be less efficient due to differences in sequence context and location of real vs. aberrant stop codons (Manuvakhova et al., 2000) . So far, three compounds have been reported induce efficient read-through stop codons in the DMD mRNA.
Gentamicin
Gentamicin is an aminoglycoside antibiotic binding to the 40S ribosomal subunit when this recognizes a stop codon (Palmer et al., 1979; Singh et al., 1979; Yoshizawa et al., 1998) . This causes the insertion of an amino acid at the stop codon position. It has first been shown that it can act on each type of stop codon without any preference in vitro (Howard et al., 2004) . Gentamicin (and negamycin) can induce the read-through stop codon in the mdx mouse (Arakawa et al., 2003; Barton-Davis et al., 1999) , the most used mouse model for DMD which carries a nonsense mutation in exon 23 (Danko et al., 1992) . However, in another report gentamicin was unable to restore dystrophin expression in the same mouse model (Dunant et al., 2003) . It was later revealed that there are a number of gentamicin isomers, which all have different read-through efficiencies, and that different gentamicin batches consist of different mixes of these isomers, which can explain these controversial results Yoshizawa et al., 1998) . Three different clinical trials have been undertaken in DMD patients using gentamicin (Malik et al., 2010b; Politano et al., 2003; Wagner et al., 2001 ). In the last one Malik and colleagues used the most active gentamicin isomer and treated the patients for 6 months. For 3 out of 12 patients the number of dystrophin positive fibers increased as assessed by immune histochemical analysis, while the effect was less clear by western blot analysis, as dystrophin was already visible before treatment, possibly due to spontaneous read-through or exon skipping (see below). Since chronic gentamicin use, is known to result in reversible kidney toxicity and irreversible ototoxicity, long term treatment with gentamicin -which would be required for DMD patients -is not realistic.
Ataluren
Ataluren, also called PTC124, was identified via in vitro screening in a luciferase assay. It is more selective for premature stop codons than regular ones, and it can be taken orally unlike gentamicin, which is administered intravenously. Studies in the mdx mouse showed that dystrophin expression could be restored after subcutaneous ataluren treatment . The compound was first tested in healthy volunteers where it was well tolerated . Then different doses were tested in DMD patients and an increase in dystrophin was reported for 18/38 patients (http://www.drugs.com/clinical_trials/ptc-therapeutics-announces-additional-resultsphase-2-study-ptc124-duchenne-muscular-dystrophy-2308.html). In a subsequent placebocontrolled phase IIb trial 174 DMD and BMD patients were treated with two doses or placebo for 48 weeks, and then all were treated with the high dose in an open label extension study (Finkel, 2010) . Treatment was well tolerated, but the primary outcome -set at 30 meter increase compared to placebo treated patients in the six minute walk test (6MWT) -was not reached, and the extension study was put on hold. From the data released (http://ptct.client.shareholder.com/releasedetail.cfm?ReleaseID=518941) it could be inferred that the low dose worked better than the high dose. It has been postulated that ataluren efficiency works through a bell shaped curve, which could explain this finding. Dystrophin analysis is pending, and different analyses of subgroups of patients is currently ongoing, as well as studies to identify the most optimal dose. Recently (May 2011) Genzyme and PTC Therapeutics announced that they are planning a follow-up clinical study for DMD patients who previously participated in the clinical trials in the UK, Europe, Israel and Australia, starting December 2011. This will provide access to ataluren to patients who have been involved in earlier clinical trials, as the trial in the USA had already been reinititated.
It has been recently published that the results obtained with the in vitro luciferase screening used to identify ataluren may have been biased, as atluren derivatives can stabilize the luciferase enzyme, giving rise to a false positive (Auld et al., 2010; Auld et al., 2009 ). However, it has been shown that ataluren has at least some read-through potential (Du et al., 2008; Welch et al., 2007) , though it is uncertain whether the levels of dystrophin restoration will be sufficient to restore muscle function.
RTC13
RTC13 is a new compound for stop codon read through. Promising preliminary data were presented at the 14th annual meeting of the American Society of Gene and Cell Therapy (http://www.cureduchenne.org/site/PageServer?pagename=research_index). In the mdx mouse model RTC13 was able to restore dystrophin expression as assessed by www.intechopen.com Muscular Dystrophy 386 western blot and immune-fluorescent analyses. Muscle fiber uptake was improved compared to the previous tested compounds. After 6 weeks of treatment mice showed improvement in muscle strength that was dependent on dystrophin recovery. Serum CK levels dropped and no toxicity was detected. Research to assess if RTC13 oral treatment is feasible is ongoing.
Nonsense mediated decay
A modifying factor which can play a role in the stop codon-read through is nonsensemediated decay (NMD). This mechanism breaks down mRNAs that carry premature stop codons, thus resulting in less target mRNAs for stop codon read through compounds. It is known that NMD efficiency varies among individuals, for different stop codons, location within the mRNA, and sequence context. In a study of cystic fibrosis patient-derived cell cultures carrying premature stop mutations in their CFTR gene, it was shown that NMD was more active in patients who did not respond to gentamicin treatment than in patients who did respond to gentamicin patients (Linde et al., 2007) . When NMD was blocked in non-responders' cells, they became more responsive to gentamicin treatment (Linde et al., 2007) . It is anticipated that NMD influences other stop codon read through approaches.
Exon skipping
The idea of the exon skipping approach is based on the observation that the milder BMD phenotype is due to mutations in which the mRNA reading frame is maintained, while the more severe DMD phenotype is caused by frame disrupting mutations. The rationale is to restore the open reading frame. Most (~65%) of the DMD causing mutations are deletions . Scientists have tried to reframe these mutations by inducing the skipping of additional exons adjacent to the out of frame deletions during pre-mRNA splicing ( Figure 2 ). The reframed mRNA will then allow translation into a smaller, partially functional, BMD-like dystrophin protein. Several groups have worked on this approach using antisense oligonucleotides (AONs) or snRNAs to induce the specific exon skipping in patients' cells in vitro and in several animal models. Fig. 2 . a. Schematic representation of the DMD genomic region encompassing exons 47 to 52. b. Deletion of exons 48 to 50 leads to an out-of-frame mRNA which can be corrected into an in-frame deletion with the use of antisense oligonucleotides (c).
There are two AON chemistries used in clinical trials for DMD: 2-O-MethylPhosphorothioates (2OMePS) and phosphorodiamidate morpholino oligomers (PMOs).
2OMePS studies
2OMePS have a methyl group at the 2'-O position of the ribose, which increases the AON affinity for RNA and avoids RNase H activation of RNA:RNA hybrids (Dominski & Kole, 1993; Sproat et al., 1989) . The PS modification is required to further increase the AON nuclease resistance, enhance cellular uptake and increase the serum half-life in vivo.
Proof of principle for the exon skipping approach and dystrophin restoration has been achieved in DMD derived cells and in murine cells (Aartsma-Rus et al., 2003; Errington et al., 2003; Mann et al., 2002; Van Deutekom et al., 2001) . To test the feasibility of the approach in vivo the mdx mouse model was mainly used. The premature stop codon in exon 23 leads to a complete absence of dystrophin, and a mild dystrophic phenotype in mice, probably due to a better regenerative capacity. Mouse dystrophin exon 23 is an in frame exon, so it is possible to skip this exon, inducing an exon 22-exon 24 junction which preserves the reading frame. Intramuscular injection of AONs targeting the exon 23 donor splice site resulted in exon 23 skipping and dystrophin synthesis (Lu et al., 2003; Mann et al., 2002) . This was accompanied by rescued sarcoglycan expression at the sarcolemma, improved titanic force, while no antibodies against the newly synthesized dystrophin were found in the serum. Gene expression profiling to evaluate AON efficacy and safety was tested in preclinical experiments. AONs were delivered using different carriers (PEI -F127 -Optison) to enhance muscle fibers uptake, or with recombinant adeno-associated virus (rAAV) expressing antisense sequences incorporated in a U7 snRNP gene. Exon skipping induced a shift towards wild type expression levels, which became statistically significant when high exon skipping levels were induced ('t Hoen et al., 2006) . Since AON-PEI complexes worsened the muscle inflammation, while F127 and Optison did not enhance AON efficacy in vivo, following experiments were performed using naked AONs. These studies all tested local intramuscular injection, while whole body treatment is required for DMD. It is known that 2OMePS AONs have a favorable serum half-life, as the PS backbones binds to serum proteins with low affinity, which prevents renal filtration and excretion in urine. Normally, 2OMePS AONs are primarily taken up by liver and kidney and the uptake in muscle is poor. However, due to the dystrophic pathology of skeletal muscle in DMD patients, AON uptake is up to 10-fold higher, resulting in sufficient AON levels for exon skipping and dystrophin restoration in skeletal muscles in mdx mice after systemic AON administration (Heemskerk et al., 2009; Lu et al., 2005) . In a comparison of intravenous, subcutaneous and intraperitoneal delivery, subcutaneous and intraperitoneal delivery showed the most preferable pharmacokinetic and pharmacodynamic profiles (lower uptake by liver and kidney), while slightly higher exon skipping levels were achieved by intravenous injections (Heemskerk et al., 2010) . Based on these results and the relative easy and low invasiveness of subcutenaous injection, this delivery route was selected for systemic clinical trials.
Clinical trials with 2OMePS
Since the exon skipping is a mutation specific approach clinical experimentation started with the largest patient cohort that would potentially benefit of skipping a single exon, i.e. exon 51 (13% of all DMD patients (Aartsma-Rus et al., 2009)). Deep phenotypic screening of two BMD patients carrying deletions that could result from exon 51 skipping, showed that these dystrophins can be largely functional (Helderman-van den Enden . A first clinical trial was coordinated by Prosensa/GSK in collaboration with the Leiden University Medical Center, using an AON targeting exon 51 (PRO051, currently called GSK2402968). This trial involved 4 patients who were each injected intramuscularly with 0.8 mg GSK2402968 in their tibialis anterior muscle. This induced specific exon 51 skipping and dystrophin recovery in 64-97% of muscle fibers at levels of 17-35% and 3-12% when quantified by immune-histochemical and western blot analysis, respectively) . After these encouraging results, the same AON was used in a subsequent Phase I/IIb clinical trial in which patients were subcutaneously injected and divided into 4 cohorts of 3 patients each based on the dose used (0.5 -2 -4 -6 mg/kg). The AON was well tolerated, and patients showed a dose dependent dystrophin recovery in 60-100% of fibers (Goemans et al., 2011) . Dystrophin amounts were quantified via fluorescent signal intensities in immune-histochemical analysis (4 to 11% dystrophin recovery) and via western blot analysis (2 to 20% dystrophin recovery). All patients were included in an open label extension study where they received weekly, subcutaneous treatments of the highest dose (6 mg/kg). The 6-minutes walk test was used as a functional outcome parameter and for most of the patients an improvement in walking distance was found after 3 months (Goemans et al., 2011) . This trial did not have a placebo group, so these results, while promising, have to be interpreted with caution. A phase III double blind clinical trial in 180 DMD patients is ongoing to determine whether long term treatment with 6 mg/kg/week GSK2402968 is safe and effective ((http://clinicaltrials.gov/ct2/show/NCT01254019?term=duchenne&rank=4). Furthermore, a trial comparing weekly and biweekly dosing at 6 mg/kg is ongoing (http://clinicaltrials.gov/ct2/show/NCT01153932?term=duchenne&rank=11). Finally, a phase I double-blind, escalating dose, randomized, placebo-controlled study assessing pharmacokinetics, safety, and tolerability in non-ambulant DMD patients is ongoing (http://clinicaltrials.gov/ct2/show/NCT01128855?term=GSK2402968&rank=3) in which patients will receive different dosages (3 -6 -9 -12 mg/kg).
PMOs
PMOs contain a morpholino moiety instead of the ribose sugar and phosphoroamidate intersubunit linkages instead of phosphodiester bonds (Kurreck, 2003) . PMOs have an affinity for RNA that is comparable to DNA oligos, are nuclease resistant and non-toxic (Summerton, 1999) . Their backbone is uncharged, which makes them difficult to transfect in vitro, and as they do not bind serum proteins, their serum half-life is limited as they are filtered out by the kidneys. PMOs have been shown to induce exon skipping and dystrophin restoration in the mdx mouse after intramuscular (Gebski et al., 2003) and systemic injections (Alter et al., 2006; Malerba et al., 2011a; Wu et al., 2010) . Upon direct comparison with 2OMePS they were shown to be more effective in inducing exon 23 skipping in the mdx mouse (Heemskerk et al., 2009 ). However, in all studies exon skipping and dystrophin restoration was only observed in skeletal muscle and not in heart, or only at very low levels unless heroic doses (up to 3 g/kg!) or microbubbles to improve uptake in heart were used (Alter et al., 2009; Wu et al., 2010) . It has become clear that repeated low dose injections are more effective than single high dosage injections (Malerba et al., 2011b; Malerba et al., 2009) , probably because of the fast PMOs clearance from the body by the kidneys (Heemskerk et al., 2010) . Survival studies show that high doses of PMOs could correct the pathology and were well tolerated (Wu et al., 2011b) . PMOs have also been used to restore dystrophin expression in the canine model of Duchenne, the golden retriever muscular dystrophy model (GRMD). GRMD dogs carry a splice site mutation in intron 6 leading exon 7 skipping. The skipping of exons 6 and 8 produces an in-frame exon-exon junction. Three dogs have been treated with an equimolar mixture of 3 morpholinos (2 targeting exon 6 and 1 targeting exon 8 in a cumulative dose of 120-200 mg/kg). PMOs were injected 5 to 11 times at weekly or biweekly intervals and tissue examination was performed 2 weeks after the last injection. Dystrophin restoration was achieved showing that exon skipping represents a possible choice also for complex mutations for which more than one exon needs to be skipped (Yokota et al., 2009 ).
Clinical trials with PMOs
Before starting clinical studies optimization of PMOs targeting exon 51 was done in cells and in the hDMD mouse (Arechavala-Gomeza et al., 2007) . Clinical studies in DMD patients using PMOs targeting exon 51 (AVI-4658) were performed in the UK by the MDEX consortium in collaboration with AVI Biopharma. Local intramuscular injection in the extensor digitorum longus (EDL) muscle induced exon skipping and dystrophin restoration. After baseline correction for the controlateral, saline injected muscle, 44 to 79% of dystrophin positive fibers were observed (Kinali et al., 2009 ) at 22-32% of wild type levels (controlateral muscle showed dystrophin levels between 4 and 14%). This led to a Phase I/IIb clinical trial in which 19 patients received 12 weekly intravenous doses of PMO. Patients were divided in cohorts based on six different doses (0.5 -1 -2 -4 -10 -20 mg/kg). PMOs were not toxic and well tolerated. The 2 high dosage cohorts showed an increase in the fluorescent intensity per fiber and dystrophin was restored in 7/19 patients. Three patients responded very well showing up to 55% of dystrophin positive fibers with an increase above 10% in mean fluorescence intensity per fiber (Cirak et al., 2011) . Based on the varying response it was concluded that dosing was not yet optimal. In a subsequent study recently initiated, weekly intravenous doses of 30 mg/kg and 50 mg/kg for 24 weeks are tested (http://clinicaltrials.gov/ct2/show/NCT01396239?term=AVI-4658&rank=1).
It is difficult to compare results for the experiments performed with the PMOs and 2OMePS, as they were performed by different groups and different analyses were used to quantify dystrophin. In a direct comparison using equal molar amounts of PMO and 2OMePS in the mdx mouse, PMOs targeting exon 23 showed higher exon skipping percentages and higher dystrophin rescue. However, experiments performed in the hDMD mouse model, carrying a copy of the complete human DMD gene, there was no clear difference between 2OMePS and PMO AONs targeting exon 44, 45, 46 and 51 upon intramuscular injection (Heemskerk et al., 2009) . Differences in the systemic trials for GSK2402968 and AVI-4658 are probably also due to the different pharmacokinetic and pharmacodynamic properties of the AONs. PMOs are extremely stable, but due to their uncharged nature they are filtered out by the kidney and their serum half-life is ~1 hour, so the time for tissue uptake is limited. The 2OMePS AONs by contrast bind serum proteins due to the PS backbone. This prevents renal clearance and increases their serum half-life to weeks. This may underlie the different staining patterns observed between PMO trials (patchy) and 2OMePS trials (more homogeneous).
AON chemistry development
While results in clinical trials are encouraging, ways to improve delivery to muscle tissues, allowing lower AON dosages would be preferred. Many approaches have been tested. Cell penetrating peptides (Jearawiriyapaisarn et al., 2008; Jearawiriyapaisarn et al., 2010; Wu et al., 2008; Yin et al., 2008) , muscle targeting peptides connected to cell penetrating peptides (Yin et al., 2009 ) and guanidine analogs (Hu et al., 2010; Wu et al., 2009) showed the most promising results in the mdx mouse and in the hDMD mouse model (Wu et al., 2011a) . Notably, pPMOs (containing arginine-rich peptides covalently bound to the morpholino AONs) have shown great potential in the mdx mouse, inducing high levels of exon skipping in skeletal muscles and heart and high levels of dystrophin rescue. Promising results using pPMOs have also been achieved in the severe mdx-utrophin -/-mouse model, which is defective for dystrophin and its homologue utrophin gene. Normally these mice do not survive beyond 3 months, but survival was increased to over a year after pPMO treatment (Goyenvalle et al., 2010) . Unfortunately, preliminary tests in non-human primates showed mild tubular degeneration in the kidney after 4 weekly injections of 9 mg/kg of pPMOs . Additional peptide conjugates will hopefully be less toxic (Yin et al., 2011) .
Antisense snRNP mediated exon skipping
Due to AON turnover and clearance, life-long treatment would be required. An alternative approach uses viral vectors expressing antisense sequences incorporated in a small nuclear ribonucleoprotein (snRNP). Adeno-associated viral vectors (AAVs) have been used to deliver the modified snRNPs as they have the best capacity to infect the muscle tissue. Different serotypes have been investigated and two molecular strategies which make use of modified U7 and U1 snRNAs have been developed. These snRNAs ensure an efficiently nuclear localization of the antisense construct, specific exon skipping and sustained dystrophin rescue in the mdx mouse model (Denti et al., 2006a; Denti et al., 2006b; Goyenvalle et al., 2004) . Optimization for human exons using splicing enhancers has been also performed (Goyenvalle et al., 2009) . Preclinical studies show the long-term benefit of the approach for up to 1 year (Denti et al., 2008) . However the clinical translation of this approach is complicated by immune response to the viral vector (see section 5.4). Thus immune-suppression will be required, especially for patients for which multiple injections to treat muscles or muscle groups will be required.
Gene editing
Gene editing is a process in which the endogenous mutated gene is modified to produce a functional dystrophin, either by correcting the DMD causing mutation or by introducing a second mutation which will rescue the effect of the first mutation. This approach has been developed using chimeric RNA-DNA oligonucleotides (RDOs or "chimeraplasts") which anneal to genomic DNA, inducing homologous recombination between the endogenous gene and the RDO, or activating the mismatch repair system. Proof of principle was demonstrated in the mdx mouse muscle (Rando et al., 2000) , in muscle precursor cells in vitro and in vivo (Bertoni & Rando, 2002) . It has been demonstrated that correction is more efficient when the RDOs target the coding strand (the non transcribed strand) (Bertoni et al., 2005) . Unfortunately, the gene conversion efficiency is as yet too low for clinical application and systemic delivery of RDOs in larger animals needs to be optimized further.
Recently another group has pioneered the use of meganucleases to correct the effect of the genetic mutation. The rationale is to correct the reading frame by introducing a micro-deletion or micro-insertion into the DMD gene. This is done by specific double strand breaks at the end of an exon which precedes a deletion or at the beginning of an exon following a deletion. Meganucleases can be engineered to specifically cut at a certain genomic position causing non-homologous end joining (NHEJ) or homologous recombination when a donor corrected sequence is present. During this process often small deletions or insertions occur, which can restore the reading frame. Proof of principle for this approach has been recently demonstrated in vitro and after local delivery in vivo, albeit at low levels (Chapdelaine et al., 2010) . The challenge of this approach will be the delivery of the meganucleases and the limited recognition of target sequences of meganucleases. The recently developed TALE nuclease system (Miller et al., 2011) allows targeting of almost all human sequences, and may provide a better alternative.
Gene therapy
Gene therapy approaches focus on providing an exogenous functional copy of the mutated gene. Gene therapy approaches are divided into 2 groups based on the type of delivery method used (viral or non-viral vector mediated) . Muscle is a difficult target tissue for viral delivery (see below). Furthermore, the huge size of the DMD gene and its 11 Kb long full length cDNA sequence (FLDYS) has been one of the bottlenecks in developing this strategy, until smaller dystrophin versions were developed to make them fit into viral vector capsids. These smaller dystrophin coding sequences, called mini-dystrophins (mDYS) and microdystrophins (μDys), were designed based on the observations that BMD patients with minor dystrophic phenotype can carry very large deletions (England et al., 1990) .
Viral vector based gene therapy
Lentiviral vectors
Lentiviral vectors have been used to treat mdx mice locally restoring dystrophin expression at different efficiencies (Kobinger et al., 2003; Li et al., 2005) . Kimura and colleagues showed that a lentivirus encoding μDys intramuscularly injected into 2 weeks old mdx 4cv mice could restore dystrophin in up to 400-1200 fibers in the tibialis anterior muscle. Mice were sacrificed at 4 different time points (4 weeks -4 months -1 year -2 years) and results were comparable over time. The virus was capable of infecting satellite cells ensuring long-term treatment efficacy (Kimura et al., 2010) . However, this may also pose a safety risk, since the transgene expression is ensured by the integration of the viral genome into the host genome. This process can cause neoplastic mutations due to the integration of the viral genome which mainly occurs close to promoter sequences (Maruggi et al., 2009) . Systemic delivery of lentiviral vectors to muscle tissue is very challenging, as muscle is post-mitotic and fibers bundles are surrounded by layers of connective tissue that filter out most viruses (>30 nm).
Adeno-associated viral vectors
Due to their small size (20 nm) adeno-associated viral vectors (AAVs) are able to efficiently infect muscles. They have been more broadly used for gene therapy for muscle diseases. They do not integrate into the host genome, making them safer than lentiviruses. At least five of the many serotypes known, show a high tropism for muscle tissues (serotypes 1, 2, 6, 8 and 9). Due to the low vector capacity mDYS and μDys have been used and efficiently delivered to skeletal muscle (Gregorevic et al., 2004 ) and heart. Very promising studies performed in the mdx mouse showed high dystrophin recovery with AAV1 (Wang et al., 2008) and AAV2 (Wang et al., 2000) , while studies in the dog model with AAV2, AAV6 (Wang et al., 2007) and AAV8 (Ohshima et al., 2009 ) raised the issue of cytotoxic immune response against the viral capsid proteins. AAV8 has also been tested in non human primates to delivery human μDys and levels up to 80% were obtained. Unfortunately these levels dropped to 40%when antibodies against the viral vector were present before the injection .
A clinical study has been also carried out in 6 DMD patients (aged 5-11 years) who received an intramuscular injection into the biceps muscle of a recombinant AAV (rAAV) vector carrying a μDYS gene . This μDYS encoded the amino-terminal actin binding domain (ABD), 5 rod repeat domains (R1, R2, R22, R23, and R24), 3 hinge domains (H1, H3 and H4), and the cysteine-rich (CR) domain of the human DMD gene. The human cytomegalovirus (CMV) immediate early promoter regulated transgene expression. Vector genomes were packaged in AAV2.5, a serotype 2 capsid variant that contains five AAV1 amino acids (one insertion and four substitutions) in the AAV2 VP1 background. AAV2.5 offers improved muscle transduction properties of AAV1 with minimal recognition by serum neutralizing antibodies. Dystrophin recovery was only very limited (a few fibers for 2 patients). Mendell and colleagues further showed the presence of T-cells recognizing dystrophin epitopes in the circulation of some of the patients. For one patient the recognized epitopes were present in the μDys and deleted in the patient DMD gene, so this perhaps was not unexpected. Interestingly, for 2 patients T-cells able to recognize dystrophin expressed in revertant fibers were identified before and after treatment. However, the continuous presence of revertant fibers suggests that the immunity against dystrophin in the blood, did not lead to an auto-immune response in the muscle tissue.
Cell therapy
Another approach to restore dystrophin expression is based on the use of stem cells with myogenic potential, which can help repair the muscle damage and also delivery a healthy (when donor cells are used) or corrected (when autologous cells are used) DMD gene.
Initial efforts focused on the transplantation of adult myoblasts able to fuse with resident damaged muscle fibers creating hybrid muscle fibers (Brussee et al., 1999; Gussoni et al., 1997) . However, this approach turned out to be hindered by poor cell survival, inability of the cells to extravagate into the muscle from the circulation, and limited migration of the injected cells within the host muscle (Qu et al., 1998) . Results of clinical studies were discouraging (Tremblay et al., 1993) . To compensate for the poor migration within muscle, a multiple injection technique has been used (up to 250 injections per square cm) (Skuk et al., 2006) , but this is only feasible for small superficial muscles.
Many adult stem cells have been tested for their ability to fuse with muscle fibers in the host dystrophic muscles in murine and canine models. Cells have been grown in vitro and then transplanted in vivo with different efficiencies. Characterization of these cells has been based on their adhesion properties in vitro or on their membrane markers. Muscle sidepopulations cells, bone-marrow-derived stem cells, muscle-derived stem cells, mesangioblasts, blood and muscle derived CD133+ stem cells and pericytes have been www.intechopen.com Duchenne Muscular Dystrophy: Therapeutic Approaches to Restore Dystrophin 393 identified (Asakura & Rudnicki, 2002; Benchaouir et al., 2007; Dezawa et al., 2005; Doherty et al., 1998; Gavina et al., 2006; Palumbo et al., 2004; Qu-Petersen et al., 2002) . Among all, satellite cells, mesangioblasts and pericytes have shown the most promising characteristics.
Satellite cells are small progenitor cells that lie between the basement membrane and the sarcolemma of the muscle fibers. They are normally in a quiescent state but they can be activated to form new muscle fibers or to fuse with damaged ones upon muscle fiber injury. They are characterized by the expression of pax3 and pax7 and they have been shown to restore dystrophin expression after transplantation in dystrophic dog muscle (Montarras et al., 2005) . Satellite cells have a great myogenic potential that is unfortunately lost when they are expanded in vitro. Encouraging results obtained in a mouse model led to a phase I clinical trial in DMD patients. Donor satellite cells were isolated from muscle biopsies from first-degree relatives of the affected children and were grown in culture (Daston et al., 1996; Seale et al., 2004) . Dystrophin production in muscle fibers was very low (~1%) and no functional or clinical improvement in the children was observed (Peault et al., 2007) .
Mesangioblasts express early but not late epithelial markers, they can transmigrate from blood vessels in tissues and they can differentiate in to muscle (Meregalli et al., 2010) .
Autologous corrected and donor mesangioblasts have shown to recover dystrophin expression in dystrophic dogs, although some dogs died due to pneumonia which may be caused by accumulation of these cells in the lungs (Sampaolesi et al., 2006) . At the moment mesangioblasts are tested in a clinical safety trial in DMD patients.
Pericytes share various markers with mesangioblasts, they can be isolated from skeletal muscle (Dellavalle et al., 2007) and also from non-muscular tissues (Crisan et al., 2008) . Dellavalle and coworkers demonstrated that pericytes have high myogenic capacity when injected into SCID/mdx mice. It still needs to be determined whether transplanted pericytes can fully reconstitute the satellite cell niche as real functional stem cells and whether systemic delivery can be performed.
The main hurdles facing stem cell treatment for DMD are the abundance of muscle (up to 40% of the bodyweight in men), which, combined with the poor efficiency of delivery of cells to muscle tissue (generally (much) below 10%), creates the need for the transplantation of huge numbers of cells in order to generate clinical benefit.
Finally the use of donor stem cells would need constant immune suppression to avoid a specific immune response against the newly formed myofibers. This issue can be solved using autologous stem cells modified ex vivo. However, this process reduces the myogenic properties of cells using current culturing methods, and may impact the behavior of the cells once they are re-injected in the patients.
Conclusion
In the last 20-25 years we have seen how basic science findings have been translated into clinical research. Many therapeutic approaches have been developed in vitro, in preclinical animal models and some of them have advanced to the clinical stage. Among all therapeutic approaches the exon skipping is at the moment the most promising for clinical application in the near future.
